Trial Profile

A Phase 1 Clinical Study of NXP900 in Subjects with Advanced Cancers

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 05 Mar 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs NXP 900 (Primary)
Indications Adenocarcinoma; Mesothelioma; Non-small cell lung cancer; Renal cancer; Solid tumours; Squamous cell cancer
Focus Adverse reactions; First in man; Therapeutic Use
Sponsors Nuvectis Pharma

Most Recent Events

27 Oct 2025 According to a Nuvectis Pharma media release, company today provided data for NXP900 poster presentations that took place last week at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston, MA.
21 Aug 2025 Planned number of patients changed from 40 to 140.
21 Aug 2025 Planned End Date changed from 1 May 2025 to 1 Jul 2027.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com